Taxotere Drug Litigation Attorneys
West Palm Beach and Palm Beach County
Taxotere (docetaxel anhydrous) is a chemotherapy drug used to treat cancer. The U.S. Food and Drug Administration (FDA) initially approved Taxotere to treat breast cancer in 1996. Over time it has been approved for use with lung, prostate, stomach, head, and neck cancer.
Taxotere, manufactured by Sanofi-Aventis, is alleged to cause alopecia and permanent hair loss. Side effects can include full body permanent or irreversible hair loss of the head hair, eyebrows, eyelashes, pubic hair, and beards for men.
According to the American Cancer Society, in 2018, it is estimated that among U.S. women and men there will be 268,670 new case of breast cancer. Almost three million U.S. women have been diagnosed with breast cancer. About three-quarters of these breast cancer patients received Taxotere.
It is alleged that Sanofi-Aventis knew as far back as the 1990’s that the drug carried an increased risk of permanent hair loss. The company has long advised physicians and patients and regulatory agencies in Canada and European Union that treatment could increase risk of permanent hair loss while the U.S. labeling stated “hair generally grows back” following treatment. It wasn’t until December 2015, that the FDA required the addition of a new U.S. warning label regarding Taxotere – “cases of permanent alopecia have been reported.
Users also allege that the drug company engaged in fraudulent marketing tactics to increase sales and failed to warn women and men of the potential serious side effects and risks.
Please note that in some matters, we may co-counsel or refer the case to another lawyer or law firm.